Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey
It’s pipeline priming time at IFM Therapeutics. And they have the money to get the job done.
The immunology experts at the discovery outfit have lined up $55.5 million in new venture backing from an expanded syndicate — still including their big believers at Atlas. And it’s not hard to figure out the motivation.
Gary Glick, who’s moving from CEO to executive chairman on this round, and his team have lined up a slate of deals for their early-stage work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.